Select region:

Clinical trials located in

Granada

Granada city is located in Spain. Currently, 20 clinical trials are being conducted in this city.

Granada, nestled at the foot of the Sierra Nevada mountains in Spain, is renowned for its rich history and cultural fusion. This city was the last stronghold of the Moors in Western Europe, falling to the Catholic Monarchs in 1492. Granada is home to the Alhambra, a stunning example of Moorish architecture, set against a backdrop of snow-capped mountains. The Albaicín, Granada’s old Muslim quarter, offers a labyrinth of narrow streets echoing the past. Additionally, Granada is known for its vibrant flamenco scene, deeply rooted in the Gitano (Romani) community.

  • CT-EU-00057072

    Testing the safety and effectiveness of astegolimab for chronic lung disease

    The aim of this study is to see if a drug called astegolimab will be effective and safe in people with a lung disease called chronic obstructive pulmonary disease, or COPD. During this study, patients will be divided into 2 groups. One group of patients will receive the drug, the remaining patients will receive a placebo to compare the results. Both groups will not know what they are getting. The study was particularly interested in people suffering from COPD (chronic obstructive pulmonary disease) who smoked or still smoke and often get sick because of it.

    BelgiumDenmarkFranceGermanyNetherlandsSpainSwedenUnited Kingdom
  • Study on genetic vaccine for unstable solid tumors

    The clinical trial is studying a new vaccine, Nous-209, in combination with pembrolizumab, a cancer drug, to treat certain solid tumors that have specific genetic changes. It is for adults with advanced colorectal, gastric, or gastroesophageal junction tumors. The study has two phases. The first phase tests different doses for safety and to find the best dose. The second phase tests how effective this combination is in treating the cancer. Patients receive the vaccine by injection and are followed for their response to the treatment. The goal is to see if this new treatment can help people with these types of tumors.

    BelgiumSpain
  • Study on luspatercept treatment for Myelodysplastic Syndrome

    This study is looking into a medication named Luspatercept and how safe and effective it is for people who have a blood condition known as lower-risk Myelodysplastic Syndrome, or LR-MDS for short. These individuals often need transfusions or have their blood refreshed with new, healthy red blood cells. The drug will be given at its highest approved dose to see what effect it has. This is being done in a controlled and careful way to make sure everything is safe for the participants in the study. People who are taking part in this study have been identified as having a very low to medium risk according to the International Prognostic Scoring System (IPSS-R). This means their disease isnt considered high-risk, which makes them suitable candidates for this research. The study is open-label, meaning everybody knows what is in the drug they are getting.

    BelgiumCzechiaFranceGermanyItalyPolandSpain
  • Study on trastuzumab deruxtecan for resistant breast cancer patients

    This clinical trial, also known as the TRANSCENDER trial, is investigating the effects of a drug called Trastuzumab Deruxtecan (T-DXd) in treating a specific type of advanced breast cancer called HER2-positive. This medicine is expected to work well in people whose disease has not responded or has had an early relapse following standard treatment. The aim is to find out how effectively this drug can slow down or possibly stop the growth of cancer cells, and how safe its use is for patients. Patients in this study will receive T-DXd intravenously every 3 weeks. The dose may be adjusted if the patient’s weight changes significantly. Treatment will continue until the cancer gets worse, side effects become too severe, or the patient decides to leave the study.

    Spain
  • Fianlimab and cemiplimab: a new treatment for melanoma patients

    The study is underway to determine the most effective treatments in preventing the recurrence of melanoma, a form of skin cancer, following surgical removal. The medicines being tested are Fianlimab and Cemiplimab together or another medicine called Pembrolizumab. The trial aims to assess whether the Fianlimab and Cemiplimab combination outperforms Pembrolizumab in preventing cancer recurrence and if patients administered Fianlimab and Cemiplimab live longer. Additionally, the study seeks insights into the impact of treatments on patients’ quality of life, the occurrence of minor or major side effects, and how these drugs behave inside the patient’s body.

    BelgiumCzechiaFranceGermanyGreeceItalyPolandRomaniaSpainUnited Kingdom
  • Examining long-term use of osimertinib in treating lung cancer

    This study is investigating a drug known as osimertinib. This includes people who have had successful surgery to remove a type of lung cancer called NSCLC. This cancer is caused by a mutation in a protein called EGFR. The aim of this study is to see if osimertinib can prevent the cancer from coming back within 5 years. The goal is also to ensure the drug’s safety for patients. Patients will receive the drug regardless of whether they received chemotherapy after surgery or not. Here are some of the issues investigators in this study will look at: how long it takes for the cancer to come back, if at all; how many people are alive without the disease after 3, 4 and 5 years; and how long people live after starting the drug. Additionally, a key part of the study is monitoring for any potential side effects.

    ItalySpainUnited Kingdom
  • Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    BelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    BelgiumBulgariaCzechiaFinlandFranceGermanyGreeceHungaryItalyNorwayPolandSlovakiaSpainSwedenUnited Kingdom
  • Evaluating dostarlimab for treating stage III colon cancer

    This research is focused on the investigation of the effect of dostarlimab on patients with severe, untreated colon cancer (T4N0 or Stage III dMMR/MSI-H). The primary objective is to assess whether dostarlimab yields superior outcomes for the patients in comparison to standard treatments. Patient monitoring will be based on tumor response and the potential impact on their quality of life resulting from the drug or disease progression.

    BelgiumFinlandFranceGermanyGreeceItalyNetherlandsNorwayPortugalSpainSwedenUnited Kingdom
  • Use of tucatinib in combination therapy for HER2-positive breast cancer

    This study examines whether tucatinib, combined with other medications, is more effective than a placebo in treating HER2-positive breast cancer. The research will also identify any side effects from the drug combination. Participants in this study have advanced breast cancer that is either unresectable (cannot be surgically removed) or metastatic (spread throughout the body). Participants will be randomly assigned to receive either tucatinib or a placebo, without knowing which one they are receiving. This method ensures the study’s fairness and accuracy. Additionally, all participants will receive trastuzumab and pertuzumab, two drugs effective against this cancer type. These will be administered every 21 days, either intravenously or subcutaneously, depending on the specific drug and combination used. The study has two main groups: one receiving a placebo and the other tucatinib, both alongside trastuzumab and pertuzumab.

    AustriaBelgiumCzechiaFinlandFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Exploring new treatment for advanced melanoma

    In this research, the researchers are examining a mix of fianlimab and cemiplimab as a potential treatment for a type of skin cancer called melanoma that is in an advanced stage or has spread to other parts of the body. It is important to see if this new medication is better than a current treatment, called pembrolizumab, in slowing down the growth of the disease. The main aim is to see how they respond to treatment, and the contribution of each drug in the mix. Additionally, the researchers will see if the drug triggers any reaction from the body’s immune system, assess how the two-drug regimen affects the patient’s physical activity, the role they play in their lives, overall health, and life quality.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Examining povorcitinib for treating hidradenitis suppurativa

    This study is about a drug called Povorcitinib, also known as INCB054707. It’s being tested on people who have moderate to severe Hidradenitis Suppurativa (HS), a painful skin condition. The trial will last for 12 weeks, and then there will be an extension period of 42 weeks. The aim of the trial is to see whether the drug is both safe, and effective enough to reduce the symptoms by at least 50%, without increasing certain symptoms like abscesses or tunnels formed by the disease. The study will also look at whether the drug significantly reduces skin pain and improves quality of life.

    AustriaBelgiumCzechiaFranceGermanyGreeceNetherlandsPolandSpain
  • Testing resiniferatoxin injection for knee pain relief in osteoarthritis

    This study is about a medical product called Resiniferatoxin (RTX-GRT7039). The researchers want to know if a one-time injection of this product can help adults who have knee pain because of a condition called osteoarthritis. The researchers will compare the results with a group of people who get a placebo. Participants won’t know whether they’re getting the real product or the placebo. The study will last about a year. It will be measured in pain level, difficulty doing physical activities, and stiffness.

    DenmarkPortugalSpainUnited Kingdom
  • Testing ravulizumab for transplant-related blood complications

    The study is examining a drug called ravulizumab used in adults and teenagers with a blood vessel disease called thrombotic microangiopathy (TMA) after a bone marrow transplant. Sometimes, new cells growing after a bone marrow transplant can cause problems in the blood vessels leading to TMA. So this study will investigate whether ravulizumab can help in this situation. In the first stage, each participant will receive the drug to determine the best dose. In the second phase, some will receive ravulizumab and best supportive care, while others will receive placebo and best supportive care. After 26 weeks of treatment, doctors will continue to monitor and record the patients’ health for another 26 weeks. Special blood tests will be done to check if the medicine is working.

    BelgiumFranceGermanyGreeceItalyNetherlandsPolandSpainSwedenUnited Kingdom
  • Evaluating Delgocitinib’s effect on Chronic Hand Eczema

    This is a study designed for teenagers aged 12 to 17 who are experiencing long-term and severe cases of hand eczema. The research aims to investigate whether a cream containing delgocitinib can be effective in treating this condition and to assess any potential side effects. Delgocitinib works by reducing inflammation, a key aspect of the body’s response in diseases like eczema. The study duration is 22 weeks, during which each participant will use either the delgocitinib cream or a cream without the active ingredient twice daily. The study will closely monitor improvements in the participants’ eczema, the impact on their daily life, and any observed side effects.

    BelgiumFrancePolandSpainUnited Kingdom
  • Testing navitoclax and ruxolitinib effective on myelofibrosis patients

    This study is trying to find out if the combination of two drugs called Navitoclax and Ruxolitinib can help people with a type of blood cancer called Myelofibrosis. Around 330 adults, who have myelofibrosis that hasn’t responded to previous treatments, will get either the new drug combination or the current best treatment for their disease. Doctors will measure whether the new combination is more effective by checking how much the size of participants’ spleens have changed during the study with scans, measuring fatigue levels and checking how well their bone marrow works.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyPolandSpainSwedenUnited Kingdom
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Monitoring the long-term safety of Nivolumab for cancer survivors

    This study is designed to understand the long-term effects of a medicine called Nivolumab in patients who have fought against various forms of cancer. In this study, the focus is on closely examining the long-term efficiency and safety of Nivolumab. Participants in the investigation encompass both current and past users of Nivolumab.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSpainUnited Kingdom
  • Testing new treatments for hidradenitis suppurativa

    A thorough study is being conducted to evaluate the safety and effectiveness of various investigational treatments for individuals with moderate to severe Hidradenitis Suppurativa (HS), a long-term skin condition characterized by small, painful lumps under the skin. The treatments being tested include CFZ533, LYS006, MAS825, LOU064, and VAY736. Participants in the study will receive one of these potential treatments, aiming to discover whether these novel therapies can significantly reduce the severity of symptoms, improve skin appearance, and enhance the overall quality of life for those affected by this challenging and often painful condition. Throughout the study, participants will undergo regular health checks, including skin assessments and evaluations of any side effects, to ensure their safety and the effectiveness of the treatments.

    AustriaBelgiumFranceGermanyHungarySpain

See more clinical trials in other cities in Spain:

.